Provided by Tiger Fintech (Singapore) Pte. Ltd.

Halozyme Therapeutics

63.02
+1.151.86%
Post-market: 61.25-1.7700-2.81%19:27 EDT
Volume:1.57M
Turnover:98.75M
Market Cap:7.76B
PE:18.37
High:63.14
Open:61.70
Low:61.54
Close:61.87
Loading ...

Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal

Investing.com
·
22 Nov 2024

U.S.-Listed Shares of Evotec Down 19.8% Premarket

THOMSON REUTERS
·
22 Nov 2024

Sector Update: Health Care Stocks Advance Premarket Friday

MT Newswires Live
·
22 Nov 2024

Update: Halozyme Therapeutics Withdraws Proposal to Acquire Evotec

MT Newswires Live
·
22 Nov 2024

Halozyme Therapeutics Ends Pursuit of Evotec

Dow Jones
·
22 Nov 2024

BUZZ-Halozyme gains after withdrawing $2.1 bln buyout offer for Evotec

Reuters
·
22 Nov 2024

BUZZ-Evotec slumps as Halozyme withdraws buyout offer

Reuters
·
22 Nov 2024

BRIEF-Halozyme Withdraws Proposal To Acquire Evotec Following Evotec's Unwillingness To Engage In Discussions

Reuters
·
22 Nov 2024

Halozyme gains after withdrawing Evotec bid

seekingalpha
·
22 Nov 2024

Halozyme withdraws $2.1 bln buyout offer for Evotec

Reuters
·
22 Nov 2024

Halozyme withdraws proposal to acquire Evotec for EUR 11.00 per share in cash

TIPRANKS
·
22 Nov 2024

Halozyme Therapeutics Withdraws Proposal to Acquire Evotec, Bloomberg Reports

MT Newswires Live
·
22 Nov 2024

Halozyme Therapeutics Inc: Reiterate Raised 2024 Guidance for Revenue of $970-$1,020 Mln and Adjusted Ebitda of $595-$625 Mln

THOMSON REUTERS
·
22 Nov 2024

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

THOMSON REUTERS
·
22 Nov 2024

Halozyme Therapeutics Inc - to Date, Evotec Has Been Unwilling to Engage With US to Explore a Potential Combination and a Company Spokesperson Has Publicly Commented That Its Goal Is to Remain an Independent Company

THOMSON REUTERS
·
22 Nov 2024

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Zacks
·
21 Nov 2024

Halozyme Therapeutics Price Target Maintained With a $68.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Nov 2024

HALO vs. FOLD: Which Stock Should Value Investors Buy Now?

Zacks
·
20 Nov 2024

Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now?

Zacks
·
19 Nov 2024

Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?

Zacks
·
19 Nov 2024